Verastem Oncology, a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for their AVMAPKI™ FAKZYNJA™ CO-PACK. This innovative treatment, which combines avutometinib capsules and defactinib tablets, is the first-ever FDA-approved therapy for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously undergone systemic therapy. The approval, which came ahead of the scheduled June 30, 2025, PDUFA action date, is based on results from the Phase 2 RAMP 201 study, which demonstrated a 44% overall response rate. The AVMAPKI FAKZYNJA CO-PACK will be available by prescription as a convenient oral combination in the U.S. Continued approval will depend on further confirmation of clinical benefits in a subsequent trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。